PH12012501494A1 - Treatment of cardiac conditions - Google Patents
Treatment of cardiac conditionsInfo
- Publication number
- PH12012501494A1 PH12012501494A1 PH1/2012/501494A PH12012501494A PH12012501494A1 PH 12012501494 A1 PH12012501494 A1 PH 12012501494A1 PH 12012501494 A PH12012501494 A PH 12012501494A PH 12012501494 A1 PH12012501494 A1 PH 12012501494A1
- Authority
- PH
- Philippines
- Prior art keywords
- treatment
- cardiac conditions
- glucagon
- dobutamine
- norepinephrine
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 229960001089 dobutamine Drugs 0.000 abstract 1
- 229940125542 dual agonist Drugs 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 239000004041 inotropic agent Substances 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000009090 positive inotropic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29665710P | 2010-01-20 | 2010-01-20 | |
| PCT/DK2011/050018 WO2011088837A1 (en) | 2010-01-20 | 2011-01-20 | Treatment of cardiac conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12012501494A1 true PH12012501494A1 (en) | 2012-10-22 |
Family
ID=43928934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2012/501494A PH12012501494A1 (en) | 2010-01-20 | 2011-01-20 | Treatment of cardiac conditions |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130157953A1 (enExample) |
| EP (1) | EP2525809B1 (enExample) |
| JP (2) | JP2013517307A (enExample) |
| KR (1) | KR20120128129A (enExample) |
| CN (1) | CN102892425A (enExample) |
| AU (1) | AU2011206979B2 (enExample) |
| BR (1) | BR112012018104A2 (enExample) |
| CA (1) | CA2786934A1 (enExample) |
| CL (1) | CL2012002037A1 (enExample) |
| EA (1) | EA026384B1 (enExample) |
| IL (1) | IL220876A0 (enExample) |
| MX (1) | MX342409B (enExample) |
| NZ (1) | NZ601167A (enExample) |
| PH (1) | PH12012501494A1 (enExample) |
| WO (1) | WO2011088837A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5635532B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| DK2370460T3 (da) | 2008-12-15 | 2014-08-04 | Zealand Pharma As | Glucagon analoger |
| ES2439499T3 (es) | 2008-12-15 | 2014-01-23 | Zealand Pharma A/S | Análogos de glucagón |
| JP5635529B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| KR101809024B1 (ko) | 2009-07-13 | 2017-12-14 | 질랜드 파마 에이/에스 | 아실화 글루카곤 유사체 |
| MX343360B (es) | 2010-04-27 | 2016-11-03 | Zealand Pharma As | Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso. |
| UY33462A (es) * | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| BR112012033225A2 (pt) * | 2010-06-24 | 2017-06-20 | Zealand Pharma As | análogos do glucagon |
| KR20140100947A (ko) | 2011-11-03 | 2014-08-18 | 질랜드 파마 에이/에스 | Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들 |
| IN2014CN04401A (enExample) * | 2011-12-23 | 2015-09-04 | Zealand Pharma As | |
| AU2013255751B2 (en) | 2012-05-03 | 2017-10-05 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| CN109456400A (zh) | 2012-07-23 | 2019-03-12 | 西兰制药公司 | 胰高血糖素类似物 |
| TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| US11065304B2 (en) * | 2012-11-20 | 2021-07-20 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
| EP2935318A1 (en) * | 2012-12-19 | 2015-10-28 | Novo Nordisk A/S | Novel glp-1 receptor agonists with cholesterol efflux activity |
| HRP20181300T1 (hr) | 2012-12-21 | 2018-10-05 | Sanofi | Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti |
| MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| US9988429B2 (en) * | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| AP2016009212A0 (en) | 2013-10-17 | 2016-05-31 | Zealand Pharma As | Acylated glucagon analogues |
| AU2014345570B2 (en) * | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| CN103724424B (zh) * | 2013-12-27 | 2015-05-27 | 浙江省农业科学院 | 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| CN107108713A (zh) * | 2014-10-10 | 2017-08-29 | 诺和诺德股份有限公司 | 稳定的基于glp‑1的glp‑1/胰高血糖素受体共激动剂 |
| WO2016066744A2 (en) | 2014-10-29 | 2016-05-06 | Zealand Pharma A/S | Gip agonist compounds and methods |
| US11135271B2 (en) | 2014-12-30 | 2021-10-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| WO2016168388A2 (en) * | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| KR20170137198A (ko) | 2015-04-16 | 2017-12-12 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AU2016287209B2 (en) | 2015-06-30 | 2023-03-02 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| PT3398961T (pt) | 2015-12-31 | 2022-09-05 | Hanmi Pharm Ind Co Ltd | Ativador triplo ativando recetor glucagon, glp-1 e gip |
| GB2566228A (en) | 2016-06-09 | 2019-03-06 | AmideBio LLC | Glucagon analogs and methods of use thereof |
| JP7208020B2 (ja) | 2016-06-29 | 2023-01-18 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途 |
| KR102502040B1 (ko) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
| CN109836503B (zh) * | 2017-11-24 | 2022-09-16 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多重活性蛋白 |
| CN115304666B (zh) * | 2017-11-24 | 2025-09-19 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的胰高血糖素类似物 |
| TWI809515B (zh) * | 2017-12-21 | 2023-07-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| EP4506017A3 (en) | 2018-01-03 | 2025-05-14 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
| WO2021083306A1 (zh) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Glp-1/gcg双受体激动剂多肽 |
| EP3842060A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled lactam co-agonists of the glucagon and glp-1 receptors |
| CN113621045A (zh) * | 2020-05-09 | 2021-11-09 | 天津药物研究院有限公司 | 具有双受体激动作用的多肽衍生物及其用途 |
| CN117202924A (zh) | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69936446T2 (de) * | 1998-02-13 | 2008-03-06 | Amylin Pharmaceuticals, Inc., San Diego | Inotropische und diuretische effekte von exendin und glp-1 |
| US6703359B1 (en) * | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
| CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US6894024B2 (en) * | 2000-10-20 | 2005-05-17 | Amylin Pharmaceuticals, Inc. | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7192922B2 (en) * | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| US7928058B2 (en) | 2006-02-22 | 2011-04-19 | Merck Sharp & Dohme Corp. | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| BRPI0807728A2 (pt) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | co-agonistas de receptor glucagon/glp-1 |
| WO2008152403A1 (en) * | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Glucagon analogues |
| KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| CN102123723B (zh) * | 2008-06-17 | 2016-05-25 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共激动剂 |
| US20100240883A1 (en) * | 2009-03-18 | 2010-09-23 | Nian Wu | Lipid-drug conjugates for drug delivery |
| TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
-
2011
- 2011-01-20 JP JP2012549249A patent/JP2013517307A/ja not_active Withdrawn
- 2011-01-20 EP EP11704174.9A patent/EP2525809B1/en active Active
- 2011-01-20 MX MX2012008440A patent/MX342409B/es active IP Right Grant
- 2011-01-20 AU AU2011206979A patent/AU2011206979B2/en not_active Ceased
- 2011-01-20 WO PCT/DK2011/050018 patent/WO2011088837A1/en not_active Ceased
- 2011-01-20 NZ NZ601167A patent/NZ601167A/en not_active IP Right Cessation
- 2011-01-20 KR KR1020127021148A patent/KR20120128129A/ko not_active Abandoned
- 2011-01-20 PH PH1/2012/501494A patent/PH12012501494A1/en unknown
- 2011-01-20 BR BR112012018104A patent/BR112012018104A2/pt not_active Application Discontinuation
- 2011-01-20 CA CA2786934A patent/CA2786934A1/en not_active Abandoned
- 2011-01-20 EA EA201290540A patent/EA026384B1/ru not_active IP Right Cessation
- 2011-01-20 US US13/574,197 patent/US20130157953A1/en not_active Abandoned
- 2011-01-20 CN CN201180012769XA patent/CN102892425A/zh active Pending
-
2012
- 2012-07-11 IL IL220876A patent/IL220876A0/en unknown
- 2012-07-20 CL CL2012002037A patent/CL2012002037A1/es unknown
-
2016
- 2016-04-01 JP JP2016074097A patent/JP6200025B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011088837A1 (en) | 2011-07-28 |
| CL2012002037A1 (es) | 2012-09-07 |
| JP2016138127A (ja) | 2016-08-04 |
| BR112012018104A2 (pt) | 2017-10-17 |
| MX342409B (es) | 2016-09-28 |
| AU2011206979A1 (en) | 2012-08-02 |
| JP2013517307A (ja) | 2013-05-16 |
| NZ601167A (en) | 2014-12-24 |
| EP2525809B1 (en) | 2016-08-03 |
| KR20120128129A (ko) | 2012-11-26 |
| EA026384B1 (ru) | 2017-04-28 |
| AU2011206979B2 (en) | 2015-09-10 |
| CA2786934A1 (en) | 2011-07-28 |
| CN102892425A (zh) | 2013-01-23 |
| JP6200025B2 (ja) | 2017-09-20 |
| EP2525809A1 (en) | 2012-11-28 |
| IL220876A0 (en) | 2012-09-24 |
| MX2012008440A (es) | 2012-08-15 |
| US20130157953A1 (en) | 2013-06-20 |
| EA201290540A1 (ru) | 2013-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012501494A1 (en) | Treatment of cardiac conditions | |
| MX370903B (es) | Composiciones de ácido percarboxílico estables y sus usos. | |
| MX2016005556A (es) | Compuestos agonistas duales de gip-glp-1 y procedimientos. | |
| EA201391033A1 (ru) | Ингибиторы bace-2 для лечения метаболических расстройств | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| MX2015008114A (es) | Derivados de exendina-4. | |
| WO2012104007A3 (de) | 7-azaindolderivate | |
| GB201116010D0 (en) | Use of alginate oligomers to enhance the effects of antifungal agents | |
| PH12014502286A1 (en) | Improving resistance to skeletal muscle fatigue | |
| MY188227A (en) | Settable compositions comprising wollastonite and pumice and methods of use | |
| MX342947B (es) | Tratamiento de diabetes tipo 2. | |
| MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| ZA201401487B (en) | Left ventricular diastolic function improving agent | |
| PT2531189E (pt) | Composição de combinação, que compreende como ingrediente activo l-carnitina ou propionil l-carnitina, para a prevenção ou o tratamento da insuficiência venosa crónica | |
| PT2770979E (pt) | Composição de reticulação melhorada administrada por iontoforese, útil para o tratamento do queratocone | |
| BR112012002353A2 (pt) | uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2 | |
| MX362111B (es) | Un metodo para mejorar la funcion hepatica. | |
| EA201491455A1 (ru) | ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| LT2460509T (lt) | Kompozicija, skirta karpų gydymui | |
| SI2702033T1 (sl) | Uporaba soli 3-karboksi-n-etil-n,n-dimteilpropan-1-amina pri zdravljenju bolezni srca in ožilja | |
| WO2011146560A3 (en) | Use of jasmonates for treating heart failure and related cardiac disorders | |
| EA201492173A1 (ru) | Дронедарон для применения при лейшманиозе, в составах и комбинациях для применения при лейшманиозе | |
| PH12014500631A1 (en) | Composition to be applied to the skin, and use thereof | |
| UA96059C2 (ru) | Применение липина как средства фригопротекторного действия | |
| ZA201206518B (en) | Combination composition,comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insuficiency |